castration-resistant prostate cancer

News

Phase I Study of PSMA Targeted 225Ac-J591 Reveals Tolerability in mCRPC

07/13/2021

225Ac-J591 receives first human study with research in PSMA targeting and dose expansion capabilities during an ongoing phase I trial.

225Ac-J591 receives first human...

07/13/2021

Oncology

Videos

Enzalutamide vs Apalutamide, Darolutamide, and Bicalutamide for Nonmetastatic CRPC

02/23/2021

Journal of Clinical Pathways

Videos

Researchers Identify Molecular Determinants of Apalutamide Response in Nonmetastatic CRPC

02/21/2021

Journal of Clinical Pathways

Videos

PTEN Loss of Function Associated With Worse Survival in Metastatic CRPC

02/18/2021

Journal of Clinical Pathways

Videos

Apalutamide Added to Abiraterone Acetate Plus Prednisone Improves Outcomes in Metastatic CRPC

02/12/2021

Journal of Clinical Pathways

News

Darolutamide for Castration-Resistant Prostate Cancer Results in 5-Year Cost Savings

11/25/2020

Journal of Clinical Pathways

Research in Review

Lower Dosage of Prostate Cancer Drug Equally Effective When Taken With Low-Fat Meal

02/17/2017

JCP Editors

Taking one-fourth the recommended dose of a standard drug with a low-fat meal is as effective as taking the recommended dose on an empty stomach for patients with castration-resistant prostate cancer, according to...

Taking...

02/17/2017

Journal of Clinical Pathways

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 13 ⁠–⁠ November 16

November 13 ⁠–⁠ November 16

November 14 ⁠–⁠ November 15

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

See Full Calendar

castration-resistant prostate cancer

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products